AmerisourceBergen

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update

Retrieved on: 
Wednesday, February 14, 2024

ISELIN, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve regulatory approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced financial results for first quarter fiscal year 2024 and provided a corporate update.

Key Points: 
  • ISELIN, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve regulatory approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced financial results for first quarter fiscal year 2024 and provided a corporate update.
  • Importantly, the first subject was enrolled in NORSE EIGHT in January 2024,” commented Russell Trenary, President and Chief Executive Officer.
  • In January 2024, Outlook Therapeutics announced that it received written agreement on the NORSE EIGHT trial protocol from the FDA under a SPA for NORSE EIGHT.
  • Outlook Therapeutics expects NORSE EIGHT topline results and resubmission of the ONS-5010 BLA by the end of calendar year 2024.

Cencora Releases 2023 ESG Report

Retrieved on: 
Wednesday, February 7, 2024

Cencora (formerly AmerisourceBergen), a global healthcare company, released its 2023 Environmental, Social and Governance (ESG) Report .

Key Points: 
  • Cencora (formerly AmerisourceBergen), a global healthcare company, released its 2023 Environmental, Social and Governance (ESG) Report .
  • The report and the related ESG Reporting Index feature detailed information on Cencora’s ESG performance and its commitment to operations that benefit the planet and people more broadly.
  • Cencora also released its 2023 Diversity, Equity and Inclusion (DEI) Progress Report , which outlines the company’s efforts to leverage benchmarks of availability for talent in the marketplace and enhance a culture of inclusion, bringing its teams under its new, united global brand, Cencora.
  • For more information on the 2023 ESG Report and DEI Progress Report, please visit: https://esg.cencora.com/reports

LiveWorld Expands Board of Directors with Two Esteemed Pharma Executives

Retrieved on: 
Wednesday, January 17, 2024

LiveWorld, Inc. (OTC Markets: LVWD) today announced the appointment of two distinguished pharmaceutical industry leaders, Jennifer Sherak and Helen S. Chang, RPH, to its Board of Directors.

Key Points: 
  • LiveWorld, Inc. (OTC Markets: LVWD) today announced the appointment of two distinguished pharmaceutical industry leaders, Jennifer Sherak and Helen S. Chang, RPH, to its Board of Directors.
  • Both Jennifer and Helen officially joined the board on January 1, 2024, bringing their wealth of experience and expertise to further guide LiveWorld's growth in the pharmaceutical sector.
  • Helen S. Chang, RPh, most recently Vice President, Marketing at Mesoblast Limited, brings a wealth of knowledge in marketing and pharmaceutical/biotech industry to the LiveWorld Board of Directors.
  • "We are delighted to welcome Jennifer and Helen to the LiveWorld Board of Directors,” said Peter Friedman, Chairman & CEO, LiveWorld, “They are both proven executive leaders in the healthcare and life science industries with business development and marketing expertise.

Vesey Street Capital Partners Announces Majority Recapitalization of Inceptua Group

Retrieved on: 
Tuesday, January 16, 2024

NEW YORK, Jan. 16, 2024 /PRNewswire/ -- Vesey Street Capital Partners, LLC ("VSCP"), a New York-based healthcare services private equity firm, announced that funds managed by VSCP have completed a majority recapitalization of Inceptua Group ("Inceptua", or the "Company").

Key Points: 
  • NEW YORK, Jan. 16, 2024 /PRNewswire/ -- Vesey Street Capital Partners, LLC ("VSCP"), a New York-based healthcare services private equity firm, announced that funds managed by VSCP have completed a majority recapitalization of Inceptua Group ("Inceptua", or the "Company").
  • AmerisourceBergen Corporation), will be joining the Company as Executive Chairman and working in partnership with VSCP, Inceptua CEO Stefan Fraenkel and the rest of the Inceptua team.
  • "Vesey Street Capital Partners is both excited and honored to be working with Doug, Stefan and the entire Inceptua team to enhance the Company's value proposition and support future growth initiatives," said Adam Feinstein, Managing Partner at VSCP.
  • Peter Krantz, founder of Inceptua, commented "The partnership with Vesey Street Capital Partners will help Inceptua's strategy of expanding its capabilities within its core business to develop additional and complementary services in-line with our customers' global needs.

Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EU

Retrieved on: 
Friday, December 22, 2023

Subsequently, as discussed with and recommended by the FDA, Outlook Therapeutics submitted a clinical trial protocol and requested a Type A meeting with the FDA for feedback.

Key Points: 
  • Subsequently, as discussed with and recommended by the FDA, Outlook Therapeutics submitted a clinical trial protocol and requested a Type A meeting with the FDA for feedback.
  • The FDA has already provided written feedback on the protocol, which Outlook Therapeutics has incorporated.
  • As of September 30, 2023, Outlook Therapeutics had cash and cash equivalents of $23.4 million.
  • On December 21, 2023, Outlook Therapeutics reached an agreement with the holder of its outstanding convertible promissory note to extend the maturity until April 1, 2024.

Healthcare Cold Chain Logistics Market Report 2023-2033 - Market Forecasted to Surpass US$17 Billion by 2023 with High Growth Through 2033 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 21, 2023

The "Healthcare Cold Chain Logistics Market Report 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Healthcare Cold Chain Logistics Market Report 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • The global healthcare cold chain logistics market is entering a phase of significant growth, alongside advancements in biopharmaceuticals, the proliferation of clinical trials, and the heightened need for vaccines, which is anticipated to fuel market expansion into 2033.
  • This comprehensive market analysis highlights the ever-increasing role of third-party logistics in healthcare, with a surge in outsourcing activities designed to streamline supply chains and optimize distribution networks.
  • The report's detailed forecasts and analyses offer a strategic advantage in an increasingly competitive and high-stakes market.

World Courier to Expand Storage Capacity and Cold Chain Capabilities With Three New Transport Stations in the United States

Retrieved on: 
Tuesday, December 19, 2023

The transport stations — which will be located in Denver, Indianapolis and San Diego — will expand World Courier’s capacity to store, handle and transport complex specialty pharmaceutical products, including those that require cryogenic storage.

Key Points: 
  • The transport stations — which will be located in Denver, Indianapolis and San Diego — will expand World Courier’s capacity to store, handle and transport complex specialty pharmaceutical products, including those that require cryogenic storage.
  • The facility in Indianapolis will be equipped with liquid nitrogen (LN2) tanks and charging capabilities, bolstering World Courier’s global network of charging centers and stations .
  • The new facilities in the United States and phased rollout of Container Freight Stations are the latest in an ongoing series of investments World Courier has undertaken to enhance and expand its capabilities globally.
  • In addition to the facility investments in the United States, World Courier will expand its presence in Denmark and Germany and increase its cold chain and cryogenic storage capabilities globally.

ACRO Announces 2024 Officers and New Members

Retrieved on: 
Wednesday, December 13, 2023

ACRO today announced that its Board of Directors has elected Peyton Howell, Chief Operating & Growth Officer at Parexel, as Chair of the association effective Jan. 1, 2024.

Key Points: 
  • ACRO today announced that its Board of Directors has elected Peyton Howell, Chief Operating & Growth Officer at Parexel, as Chair of the association effective Jan. 1, 2024.
  • Lisa Moneymaker, Chief Technology Officer & Chief Product Officer at Saama, was elected Vice Chair.
  • Ms. Howell serves on the Board of Directors of Tandem Diabetes Care (NASDAQ: TNDM), a medical device manufacturer, and has represented Parexel on the ACRO Board since 2020.
  • and YPrime, an eClinical trial management solutions company, as its newest members.

Cencora Announces Common Share Repurchase From Walgreens Boots Alliance

Retrieved on: 
Thursday, November 9, 2023

Cencora, Inc. (NYSE: COR), formerly AmerisourceBergen Corporation, today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $250 million in concurrence with Walgreens Boots Alliance’s entry into certain variable pre-paid forward transactions executed in reliance on Rule 144 under the Securities Act of 1933, as amended.

Key Points: 
  • Cencora, Inc. (NYSE: COR), formerly AmerisourceBergen Corporation, today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $250 million in concurrence with Walgreens Boots Alliance’s entry into certain variable pre-paid forward transactions executed in reliance on Rule 144 under the Securities Act of 1933, as amended.
  • Cencora intends to repurchase shares from Walgreens Boots Alliance at the per share price equal to the price in the Rule 144 transaction.
  • The concurrent share repurchase will be made under Cencora’s share repurchase program and the repurchased shares will be held in treasury.

PatientPoint Welcomes Jeff Vacirca, MD, FACP, and Amy Grogg, PharmD, to Board of Directors

Retrieved on: 
Wednesday, December 13, 2023

CINCINNATI, Dec. 13, 2023 /PRNewswire/ -- PatientPoint® today announced the addition of Jeffrey Vacirca, MD, FACP, and Amy Grogg, PharmD, to its board of directors. Dr. Vacirca will serve as an independent board member while Ms. Grogg will serve as a board advisor. Taken together, Dr. Vacirca and Ms. Grogg bring deep care delivery and life science commercialization expertise to PatientPoint's board.

Key Points: 
  • CINCINNATI, Dec. 13, 2023 /PRNewswire/ -- PatientPoint® today announced the addition of Jeffrey Vacirca, MD, FACP, and Amy Grogg, PharmD, to its board of directors.
  • Dr. Vacirca will serve as an independent board member while Ms. Grogg will serve as a board advisor.
  • Taken together, Dr. Vacirca and Ms. Grogg bring deep care delivery and life science commercialization expertise to PatientPoint's board.
  • Ms. Grogg brings nearly 30 years of pharmaceutical commercialization experience to the PatientPoint board.